Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Depreciation and Depletion: 2022-2025

Historic Depreciation and Depletion for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $442,000.

  • Stoke Therapeutics' Depreciation and Depletion fell 18.15% to $442,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 17.00%. This contributed to the annual value of $2.2 million for FY2024, which is 12.00% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Depreciation and Depletion is $442,000, which was down 0.90% from $446,000 recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Depreciation and Depletion high stood at $655,000 for Q4 2023, and its period low was $247,000 during Q1 2022.
  • Over the past 3 years, Stoke Therapeutics' median Depreciation and Depletion value was $549,000 (recorded in 2024), while the average stood at $551,364.
  • As far as peak fluctuations go, Stoke Therapeutics' Depreciation and Depletion skyrocketed by 141.70% in 2023, and later declined by 18.61% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Depreciation and Depletion stood at $609,000 in 2022, then increased by 7.55% to $655,000 in 2023, then dropped by 16.18% to $549,000 in 2024, then decreased by 18.15% to $442,000 in 2025.
  • Its last three reported values are $442,000 in Q3 2025, $446,000 for Q2 2025, and $477,000 during Q1 2025.